231 related articles for article (PubMed ID: 15921913)
1. Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity.
Brun MP; Braud E; Angotti D; Mondésert O; Quaranta M; Montes M; Miteva M; Gresh N; Ducommun B; Garbay C
Bioorg Med Chem; 2005 Aug; 13(16):4871-9. PubMed ID: 15921913
[TBL] [Abstract][Full Text] [Related]
2. Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties.
Braud E; Goddard ML; Kolb S; Brun MP; Mondésert O; Quaranta M; Gresh N; Ducommun B; Garbay C
Bioorg Med Chem; 2008 Oct; 16(19):9040-9. PubMed ID: 18789703
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
Schepetkin IA; Karpenko AS; Khlebnikov AI; Shibinska MO; Levandovskiy IA; Kirpotina LN; Danilenko NV; Quinn MT
Eur J Med Chem; 2019 Dec; 183():111719. PubMed ID: 31563013
[TBL] [Abstract][Full Text] [Related]
4. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.
Lazo JS; Nemoto K; Pestell KE; Cooley K; Southwick EC; Mitchell DA; Furey W; Gussio R; Zaharevitz DW; Joo B; Wipf P
Mol Pharmacol; 2002 Apr; 61(4):720-8. PubMed ID: 11901209
[TBL] [Abstract][Full Text] [Related]
5. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase.
Brisson M; Nguyen T; Vogt A; Yalowich J; Giorgianni A; Tobi D; Bahar I; Stephenson CR; Wipf P; Lazo JS
Mol Pharmacol; 2004 Oct; 66(4):824-33. PubMed ID: 15231869
[TBL] [Abstract][Full Text] [Related]
6. Naphthoquinone analogs as inactivators of cdc25 phosphatase.
Ham SW; Park J; Lee SJ; Kim W; Kang K; Choi KH
Bioorg Med Chem Lett; 1998 Sep; 8(18):2507-10. PubMed ID: 9873570
[TBL] [Abstract][Full Text] [Related]
7. Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening.
Lavecchia A; Di Giovanni C; Pesapane A; Montuori N; Ragno P; Martucci NM; Masullo M; De Vendittis E; Novellino E
J Med Chem; 2012 May; 55(9):4142-58. PubMed ID: 22524450
[TBL] [Abstract][Full Text] [Related]
8. A novel synthetic inhibitor of CDC25 phosphatases: BN82002.
Brezak MC; Quaranta M; Mondésert O; Galcera MO; Lavergne O; Alby F; Cazales M; Baldin V; Thurieau C; Harnett J; Lanco C; Kasprzyk PG; Prevost GP; Ducommun B
Cancer Res; 2004 May; 64(9):3320-5. PubMed ID: 15126376
[TBL] [Abstract][Full Text] [Related]
9. Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK.
Kar S; Wang M; Ham SW; Carr BI
Biochem Pharmacol; 2006 Nov; 72(10):1217-27. PubMed ID: 16930563
[TBL] [Abstract][Full Text] [Related]
10. CDC25A and B dual-specificity phosphatase inhibitors: potential agents for cancer therapy.
Lavecchia A; Di Giovanni C; Novellino E
Curr Med Chem; 2009; 16(15):1831-49. PubMed ID: 19442149
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of novel bis-thiazolone derivatives as micromolar CDC25 phosphatase inhibitors: effect of dimerisation on phosphatase inhibition.
Sarkis M; Tran DN; Kolb S; Miteva MA; Villoutreix BO; Garbay C; Braud E
Bioorg Med Chem Lett; 2012 Dec; 22(24):7345-50. PubMed ID: 23141909
[TBL] [Abstract][Full Text] [Related]
12. Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties.
Peyregne VP; Kar S; Ham SW; Wang M; Wang Z; Carr BI
Mol Cancer Ther; 2005 Apr; 4(4):595-602. PubMed ID: 15827333
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of novel coumarin-based inhibitors of Cdc25 phosphatases.
Valente S; Bana E; Viry E; Bagrel D; Kirsch G
Bioorg Med Chem Lett; 2010 Oct; 20(19):5827-30. PubMed ID: 20800482
[TBL] [Abstract][Full Text] [Related]
14. Activity of novel Cdc25 inhibitors and preliminary evaluation of their potentiation of chemotherapeutic drugs in human breast cancer cells.
Brault L; Bagrel D
Life Sci; 2008 Jan; 82(5-6):315-23. PubMed ID: 18191419
[TBL] [Abstract][Full Text] [Related]
15. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.
Park H; Bahn YJ; Ryu SE
Bioorg Med Chem Lett; 2009 Aug; 19(15):4330-4. PubMed ID: 19497739
[TBL] [Abstract][Full Text] [Related]
16. Shikonin inhibits cancer cell cycling by targeting Cdc25s.
Zhang S; Gao Q; Li W; Zhu L; Shang Q; Feng S; Jia J; Jia Q; Shen S; Su Z
BMC Cancer; 2019 Jan; 19(1):20. PubMed ID: 30616572
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B.
George Rosenker KM; Paquette WD; Johnston PA; Sharlow ER; Vogt A; Bakan A; Lazo JS; Wipf P
Bioorg Med Chem; 2015 Jun; 23(12):2810-8. PubMed ID: 25703307
[TBL] [Abstract][Full Text] [Related]
18. Synthetic small molecule Cdc25 phosphatases inhibitors.
Garuti L; Roberti M; Pizzirani D
Curr Med Chem; 2008; 15(6):573-80. PubMed ID: 18336271
[TBL] [Abstract][Full Text] [Related]
19. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.
Lazo JS; Aslan DC; Southwick EC; Cooley KA; Ducruet AP; Joo B; Vogt A; Wipf P
J Med Chem; 2001 Nov; 44(24):4042-9. PubMed ID: 11708908
[TBL] [Abstract][Full Text] [Related]
20. Structure-based development of novel triazoles and related thiazolotriazoles as anticancer agents and Cdc25A/B phosphatase inhibitors. Synthesis, in vitro biological evaluation, molecular docking and in silico ADME-T studies.
Rostom SAF; Badr MH; Abd El Razik HA; Ashour HMA
Eur J Med Chem; 2017 Oct; 139():263-279. PubMed ID: 28803043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
